HUE049543T2 - Variáns flavivírusburok-szekvenciák és alkalmazásaik - Google Patents

Variáns flavivírusburok-szekvenciák és alkalmazásaik

Info

Publication number
HUE049543T2
HUE049543T2 HUE17726515A HUE17726515A HUE049543T2 HU E049543 T2 HUE049543 T2 HU E049543T2 HU E17726515 A HUE17726515 A HU E17726515A HU E17726515 A HUE17726515 A HU E17726515A HU E049543 T2 HUE049543 T2 HU E049543T2
Authority
HU
Hungary
Prior art keywords
envelope sequences
flavivirus envelope
variant
variant flavivirus
sequences
Prior art date
Application number
HUE17726515A
Other languages
English (en)
Hungarian (hu)
Inventor
Peter Laing
Original Assignee
Excivion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Excivion Ltd filed Critical Excivion Ltd
Publication of HUE049543T2 publication Critical patent/HUE049543T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
HUE17726515A 2016-05-20 2017-05-22 Variáns flavivírusburok-szekvenciák és alkalmazásaik HUE049543T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1608896.5A GB2550418A (en) 2016-05-20 2016-05-20 An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies

Publications (1)

Publication Number Publication Date
HUE049543T2 true HUE049543T2 (hu) 2020-09-28

Family

ID=56369688

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17726515A HUE049543T2 (hu) 2016-05-20 2017-05-22 Variáns flavivírusburok-szekvenciák és alkalmazásaik

Country Status (18)

Country Link
US (2) US11028133B2 (enExample)
EP (2) EP3458471B1 (enExample)
JP (1) JP7121396B2 (enExample)
KR (1) KR20190008896A (enExample)
CN (1) CN109415414A (enExample)
AU (1) AU2017268479B2 (enExample)
BR (1) BR112018073681A2 (enExample)
CA (1) CA3025076A1 (enExample)
DK (1) DK3458471T3 (enExample)
GB (2) GB2550418A (enExample)
HU (1) HUE049543T2 (enExample)
IL (1) IL263054A (enExample)
MX (1) MX2018014198A (enExample)
PE (1) PE20190130A1 (enExample)
PH (1) PH12018502441A1 (enExample)
RU (1) RU2018142835A (enExample)
SG (1) SG11201810157QA (enExample)
WO (2) WO2017201543A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2550418A (en) * 2016-05-20 2017-11-22 Laing Peter An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies
US10849943B2 (en) * 2016-06-23 2020-12-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vaccine compositions comprising an attenuated mutant Zika virus
EP3621645A4 (en) 2017-05-10 2021-01-27 University of Massachusetts BIVALENT VACCINES AGAINST DENGUE / HEPATITIS B
TWI658848B (zh) * 2018-02-13 2019-05-11 National Tsing Hua University 茲卡病毒疫苗組合物及其應用
CN109627294B (zh) * 2018-12-29 2020-10-09 四川大学 一种正确折叠的重组狂犬病毒g蛋白胞外段及其潜在应用
WO2020198865A1 (en) * 2019-04-03 2020-10-08 The University Of British Columbia Oligopeptides for quantitative viral proteomic analysis methods and uses
JP7725465B2 (ja) * 2019-11-07 2025-08-19 中国科学院微生物研究所 ジカ・デングワクチン及びその使用
CN117157524A (zh) * 2020-10-07 2023-12-01 赛诺菲巴斯德有限公司 改良的诊断测试
CA3198059A1 (en) * 2020-10-07 2022-04-14 Sanofi Pasteur Improved diagnostic tests
GB202019843D0 (en) 2020-12-16 2021-01-27 Coronex Ltd Lateral flow tests
EP4602057A1 (en) * 2022-10-11 2025-08-20 University of Maryland, Baltimore Engineered flavivirus envelope glycoprotein immunogenic compositions and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110669A (en) 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
WO2007015783A2 (en) 2005-07-22 2007-02-08 Research Development Foundation Attenuated strains of flaviviruses , and uses thereof
US7943148B1 (en) 2007-04-04 2011-05-17 The United States Of America As Represented By The Secretary Of The Army Amino acid sites in Flavivirus E proteins useful for development of diagnostics and vaccines
EP2834265A4 (en) * 2012-04-02 2015-10-14 Univ North Carolina METHOD AND COMPOSITIONS FOR DENGUE VIRUS EPITOPES
GB201413086D0 (en) * 2014-07-23 2014-09-03 Imp Innovations Ltd And Inst Pasteur Methods
GB2550418A (en) * 2016-05-20 2017-11-22 Laing Peter An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies

Also Published As

Publication number Publication date
DK3458471T3 (da) 2020-07-06
GB201719423D0 (en) 2018-01-03
AU2017268479A1 (en) 2018-12-06
BR112018073681A2 (pt) 2019-02-26
EP3458471A1 (en) 2019-03-27
US11401307B2 (en) 2022-08-02
GB2550418A (en) 2017-11-22
WO2018215495A1 (en) 2018-11-29
MX2018014198A (es) 2019-08-21
CA3025076A1 (en) 2017-11-23
RU2018142835A (ru) 2020-06-22
PE20190130A1 (es) 2019-01-17
US20200215180A1 (en) 2020-07-09
GB201608896D0 (en) 2016-07-06
IL263054A (en) 2019-01-31
AU2017268479B2 (en) 2021-04-01
US11028133B2 (en) 2021-06-08
CN109415414A (zh) 2019-03-01
KR20190008896A (ko) 2019-01-25
EP3630796A1 (en) 2020-04-08
US20190300580A1 (en) 2019-10-03
PH12018502441A1 (en) 2019-05-15
WO2017201543A1 (en) 2017-11-23
SG11201810157QA (en) 2018-12-28
JP2019520058A (ja) 2019-07-18
JP7121396B2 (ja) 2022-08-18
EP3458471B1 (en) 2020-03-25

Similar Documents

Publication Publication Date Title
IL275468A (en) Incretin analogs and their use
IL275469A (en) Incretin analogs and their use
IL263054A (en) Various flavivirus envelope sequences and their uses
IL287825A (en) Structures of sirp-alpha variant and their uses
IL254977B (en) Biological conjugates and their uses
IL256137B (en) Corneal implant and its use
IL265796A (en) Preparations comprising short peptides derived from pedf and their uses
ZA201801052B (en) Combinations and uses thereof
IL256020B (en) Igfbp3 and uses thereof
SG11201705759SA (en) Cytotoxic hexim1 peptides and uses thereof
IL248424B (en) Neuroprotective substances and their uses
IL254241A0 (en) Etv2 and its uses
IL254287A0 (en) Cyclic galanin analogs and uses thereof
IL273671A (en) Cornoline variants and their use
IL248863A0 (en) Preparations containing il-31 and their use
SG11201610918RA (en) Peptides and uses thereof
GB201911959D0 (en) Immunogenic compositions and uses therefor
PL3221860T3 (pl) Zespół podstawy i korpusu
IL248576A0 (en) Anti-lice preparation and its uses
GB201403765D0 (en) ORCTL3 Sequences and their uses